B+
Bull case
25%
Probability
Target price
$510.00
+22.2% vs current
CHE
ChemedBNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$443.00
+6.2% vs current
B-
Bear case
25%
Probability
Target price
$360.00
-13.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+54.1
Score
AI commentary
Primary-source coverage is solid (Q1 release, 10-Q, and annual-meeting 8-K), but external analyst revision/target coverage in the packet is thin and no social context is available. The stock looks roughly fairly valued near the 443 median target, so this is a cautious monitoring view rather than a high-conviction rerating story.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-23eventQ1 results and guidance resetMedium impact
Chemed reported Q1 2026 revenue of $657.5M and adjusted diluted EPS of $5.65, then raised full-year 2026 EPS guidance to $24.00-$24.75 on stronger VITAS performance and higher share repurchase activity. [#IR-2026-04-23]
2026-05-19catalystSay-on-pay failed at the annual meetingMedium impact
At the May 18 annual meeting, the non-binding executive compensation proposal failed, with more votes against than for, creating a small governance overhang rather than a core thesis driver. [#8-K-2026-05-19]
2026-12-31catalystVITAS growth stays the main earnings driverMedium impact
VITAS admissions rose 6.9%, no Florida Medicare Cap billing limitation is anticipated for 2026, and management lifted 2026 ADC, revenue, and EBITDA-margin guidance after quicker-than-expected normalization. [#IR-2026-04-23][#10-Q-2026-04-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology